Somewhat Positive News Coverage Somewhat Unlikely to Affect Spero Therapeutics (SPRO) Stock Price
Media headlines about Spero Therapeutics (NASDAQ:SPRO) have been trending somewhat positive recently, according to Accern Sentiment. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Spero Therapeutics earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.0249799663774 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s rankings:
- ValuEngine Upgrades Spero Therapeutics (SPRO) to “Sell” (americanbankingnews.com)
- Analysts Expect Spero Therapeutics Inc (SPRO) to Announce -$1.56 Earnings Per Share (americanbankingnews.com)
- Spero Therapeutics Inc (SPRO) Given Consensus Rating of “Hold” by Brokerages (americanbankingnews.com)
- Contrasting Spero Therapeutics (SPRO) and The Competition (americanbankingnews.com)
- Spero Announces Appointment of David P. Southwell to its Board of Directors (finance.yahoo.com)
Several equities research analysts have commented on SPRO shares. Oppenheimer started coverage on shares of Spero Therapeutics in a research note on Monday, November 27th. They issued a “buy” rating and a $30.00 price objective for the company. Cowen started coverage on shares of Spero Therapeutics in a research note on Monday, November 27th. They issued an “outperform” rating for the company. Stifel Nicolaus started coverage on shares of Spero Therapeutics in a research note on Monday, November 27th. They issued a “buy” rating and a $26.00 price objective for the company. Bank of America started coverage on shares of Spero Therapeutics in a research note on Monday, November 27th. They issued a “neutral” rating for the company. Finally, Zacks Investment Research upgraded shares of Spero Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a research note on Tuesday, January 30th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $23.33.
Spero Therapeutics (NASDAQ:SPRO) last released its earnings results on Thursday, December 14th. The company reported ($36.02) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($2.43) by ($33.59). The firm had revenue of $0.60 million for the quarter, compared to analysts’ expectations of $0.20 million. equities research analysts predict that Spero Therapeutics will post -8.52 earnings per share for the current year.
About Spero Therapeutics
Spero Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. The Company is developing a portfolio of novel product candidates, including SPR994, Potentiator Platform (SPR741 and SPR206), and SPR720.
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.